BOLT Bolt Biotherapeutics, Inc.

NASDAQ
$5.10

Bolt Biotherapeutics, Inc. (BOLT) is expected to report earnings on February 11, 2027, after the market close. The consensus earnings estimate is a loss of $2.01 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -15.4% since its last earnings release on November 12, 2026.

Bolt Biotherapeutics Beat Consensus Estimates
Thursday, November 12, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 11
Thursday · 4:05 PM ET
Earnings Whisper
-
vs ($2.01)
Rev est $1.5M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $5.57

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Inc. is a clinical-stage immuno-oncology company. It engages in the discovery, development, and commercialization of pharmaceutical products. The company's principal product includes BDC-1001. Bolt Biotherapeutics Inc. is based in Redwood city, California.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.